Specific immune response to stem cell pluripotency marker SOX2 in patients with monoclonal gammapathy is associated with a favorable prognosis

References

[1] Kyle R., Therneau T., Rajkumar V. et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance. N. Engl. J. Med. 2006; 354: 1362-9.

[2] Dhodapkar M., Krasovsky J., Osman K. and Geller M. Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy. J. Exp. Med. 2003; 198(11): 1753-7.

[3] Wegner M. and Stolt C. From stem cells to neurons and glia: a Soxist’s view of neural development. Trends Neurosci. 2005; 28: 583-8.

[4] Boyer L., Lee T., Cole M. et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005; 122: 947-56.

[5] Matsui W., Huff C., Wang Q. et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004; 103: 2332-6.

RIGHTS & PERMISSIONS

Eco-Vector